Review



ag-specific tr1 cell medicinal product  (TxCell Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    TxCell Inc ag-specific tr1 cell medicinal product
    T regulatory type 1 <t>(Tr1)-mediated</t> suppression in vivo . In steady-state condition, Tr1 cells reside in the spleen and circulate in the periphery. During inflammation, Tr1 cells are recruited to the site of tissue injury (i.e., after infections, autoimmune reactions, or transplantation) and are activated by professional antigen-presenting cells [APCs; dendritic cells (DCs)] via their T cell receptor, thus by their cognate antigen (Ag). Upon activation, Tr1 cells secrete IL-10 and TGF-β and (1) directly inhibit effector T cell (i.e., Th1 and Th17 cells) proliferation and pro-inflammatory cytokines production and (2) indirectly inhibit effector T cells by modulating professional APCs (i.e., downregulation of costimulatory and HLA class II expression and inhibition of pro-inflammatory cytokine secretion). (3) Tr1 cells can suppress effector T cells by cell-to-cell contact-mediated mechanisms, (4) suppress CD8 + T cell responses (i.e., proliferation and IFN-γ production), and (5) mediate bystander suppression by specifically killing professional APCs [DC or macrophages (M)], thus preventing naive T (Tn) cell priming and reactivation of effector T cells (i.e., Th1 and Th17 cells). Concomitantly, (6) Tr1 cells via IL-10 and TGF-β promote the induction of tolerogenic DC and anti-inflammatory macrophages (M2), which in turn promote de novo induction of Tr1 cells and T regulatory cells (Tregs), restoring tissue homeostasis and promoting long-term tolerance.
    Ag Specific Tr1 Cell Medicinal Product, supplied by TxCell Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ag-specific+tr1+cell+medicinal+product/pmc05818395-90-6-17?v=TxCell+Inc
    Average 90 stars, based on 1 article reviews
    ag-specific tr1 cell medicinal product - by Bioz Stars, 2026-07
    90/100 stars

    Images

    1) Product Images from "Engineered T Regulatory Type 1 Cells for Clinical Application"

    Article Title: Engineered T Regulatory Type 1 Cells for Clinical Application

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2018.00233

    T regulatory type 1 (Tr1)-mediated suppression in vivo . In steady-state condition, Tr1 cells reside in the spleen and circulate in the periphery. During inflammation, Tr1 cells are recruited to the site of tissue injury (i.e., after infections, autoimmune reactions, or transplantation) and are activated by professional antigen-presenting cells [APCs; dendritic cells (DCs)] via their T cell receptor, thus by their cognate antigen (Ag). Upon activation, Tr1 cells secrete IL-10 and TGF-β and (1) directly inhibit effector T cell (i.e., Th1 and Th17 cells) proliferation and pro-inflammatory cytokines production and (2) indirectly inhibit effector T cells by modulating professional APCs (i.e., downregulation of costimulatory and HLA class II expression and inhibition of pro-inflammatory cytokine secretion). (3) Tr1 cells can suppress effector T cells by cell-to-cell contact-mediated mechanisms, (4) suppress CD8 + T cell responses (i.e., proliferation and IFN-γ production), and (5) mediate bystander suppression by specifically killing professional APCs [DC or macrophages (M)], thus preventing naive T (Tn) cell priming and reactivation of effector T cells (i.e., Th1 and Th17 cells). Concomitantly, (6) Tr1 cells via IL-10 and TGF-β promote the induction of tolerogenic DC and anti-inflammatory macrophages (M2), which in turn promote de novo induction of Tr1 cells and T regulatory cells (Tregs), restoring tissue homeostasis and promoting long-term tolerance.
    Figure Legend Snippet: T regulatory type 1 (Tr1)-mediated suppression in vivo . In steady-state condition, Tr1 cells reside in the spleen and circulate in the periphery. During inflammation, Tr1 cells are recruited to the site of tissue injury (i.e., after infections, autoimmune reactions, or transplantation) and are activated by professional antigen-presenting cells [APCs; dendritic cells (DCs)] via their T cell receptor, thus by their cognate antigen (Ag). Upon activation, Tr1 cells secrete IL-10 and TGF-β and (1) directly inhibit effector T cell (i.e., Th1 and Th17 cells) proliferation and pro-inflammatory cytokines production and (2) indirectly inhibit effector T cells by modulating professional APCs (i.e., downregulation of costimulatory and HLA class II expression and inhibition of pro-inflammatory cytokine secretion). (3) Tr1 cells can suppress effector T cells by cell-to-cell contact-mediated mechanisms, (4) suppress CD8 + T cell responses (i.e., proliferation and IFN-γ production), and (5) mediate bystander suppression by specifically killing professional APCs [DC or macrophages (M)], thus preventing naive T (Tn) cell priming and reactivation of effector T cells (i.e., Th1 and Th17 cells). Concomitantly, (6) Tr1 cells via IL-10 and TGF-β promote the induction of tolerogenic DC and anti-inflammatory macrophages (M2), which in turn promote de novo induction of Tr1 cells and T regulatory cells (Tregs), restoring tissue homeostasis and promoting long-term tolerance.

    Techniques Used: In Vivo, Transplantation Assay, Activation Assay, Expressing, Inhibition

    Protocols to generate/expand T regulatory type 1 (Tr1) cells. (A) Tr1-enriched cell lines. Donor-derived PBMC or CD4 + T cells are stimulated with host-derived monocytes in the presence of recombinant human IL-10 for 10 days. Alternatively, PBMC or CD4 + T cells are cultured for 10 days with allogenic dendritic cell (DC)-10, differentiated in vitro from peripheral blood monocytes with GM-CSF/IL-4/IL-10, in the presence of recombinant human IL-10 for 10 days . To generate T-allo10 cells, donor-derived T cells are cultured with host-derived DC-10 (Bacchetta and Roncarolo, unpublished data), whereas to induce host-derived T10 cells, T cells are stimulated with donor-derived DC-10 . (B) Tr1 cell clones. PBMC are stimulated with antigen (Ag; i.e., ovalbumin or collagen II) in the presence of IL-2 and IL-4 to enrich/expand Ag-specific T cells, followed by T cell cloning and expansion of the T cell clones using Schneider cells . (C) Tr1-like cell lines. Human CD4 + T cells are preactivated for 48 h with soluble anti-CD3/CD28 mAbs and IL-2 and then transduced with lentiviral vector (LV)-IL-10 overnight. Transduced T cells are isolated and expanded in feeder mixture . To generate allospecific IL-10-transduced cells, naive CD4 + T cells are stimulated with allogeneic DC and transduced with LV-IL-10 upon secondary stimulation. After selection, IL-10-trasduced cells are expanded in vitro with feeder mixture .
    Figure Legend Snippet: Protocols to generate/expand T regulatory type 1 (Tr1) cells. (A) Tr1-enriched cell lines. Donor-derived PBMC or CD4 + T cells are stimulated with host-derived monocytes in the presence of recombinant human IL-10 for 10 days. Alternatively, PBMC or CD4 + T cells are cultured for 10 days with allogenic dendritic cell (DC)-10, differentiated in vitro from peripheral blood monocytes with GM-CSF/IL-4/IL-10, in the presence of recombinant human IL-10 for 10 days . To generate T-allo10 cells, donor-derived T cells are cultured with host-derived DC-10 (Bacchetta and Roncarolo, unpublished data), whereas to induce host-derived T10 cells, T cells are stimulated with donor-derived DC-10 . (B) Tr1 cell clones. PBMC are stimulated with antigen (Ag; i.e., ovalbumin or collagen II) in the presence of IL-2 and IL-4 to enrich/expand Ag-specific T cells, followed by T cell cloning and expansion of the T cell clones using Schneider cells . (C) Tr1-like cell lines. Human CD4 + T cells are preactivated for 48 h with soluble anti-CD3/CD28 mAbs and IL-2 and then transduced with lentiviral vector (LV)-IL-10 overnight. Transduced T cells are isolated and expanded in feeder mixture . To generate allospecific IL-10-transduced cells, naive CD4 + T cells are stimulated with allogeneic DC and transduced with LV-IL-10 upon secondary stimulation. After selection, IL-10-trasduced cells are expanded in vitro with feeder mixture .

    Techniques Used: Derivative Assay, Recombinant, Cell Culture, In Vitro, Clone Assay, Cloning, Transduction, Plasmid Preparation, Isolation, Selection

    Tr1 cells in clinical and preclinical development.
    Figure Legend Snippet: Tr1 cells in clinical and preclinical development.

    Techniques Used: Clone Assay, In Vitro, In Vivo, Functional Assay



    Similar Products

    ag-specific tr1 cell medicinal product  (TxCell Inc)
    90
    TxCell Inc ag-specific tr1 cell medicinal product
    T regulatory type 1 <t>(Tr1)-mediated</t> suppression in vivo . In steady-state condition, Tr1 cells reside in the spleen and circulate in the periphery. During inflammation, Tr1 cells are recruited to the site of tissue injury (i.e., after infections, autoimmune reactions, or transplantation) and are activated by professional antigen-presenting cells [APCs; dendritic cells (DCs)] via their T cell receptor, thus by their cognate antigen (Ag). Upon activation, Tr1 cells secrete IL-10 and TGF-β and (1) directly inhibit effector T cell (i.e., Th1 and Th17 cells) proliferation and pro-inflammatory cytokines production and (2) indirectly inhibit effector T cells by modulating professional APCs (i.e., downregulation of costimulatory and HLA class II expression and inhibition of pro-inflammatory cytokine secretion). (3) Tr1 cells can suppress effector T cells by cell-to-cell contact-mediated mechanisms, (4) suppress CD8 + T cell responses (i.e., proliferation and IFN-γ production), and (5) mediate bystander suppression by specifically killing professional APCs [DC or macrophages (M)], thus preventing naive T (Tn) cell priming and reactivation of effector T cells (i.e., Th1 and Th17 cells). Concomitantly, (6) Tr1 cells via IL-10 and TGF-β promote the induction of tolerogenic DC and anti-inflammatory macrophages (M2), which in turn promote de novo induction of Tr1 cells and T regulatory cells (Tregs), restoring tissue homeostasis and promoting long-term tolerance.
    Ag Specific Tr1 Cell Medicinal Product, supplied by TxCell Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ag-specific+tr1+cell+medicinal+product/pmc05818395-90-6-17?v=TxCell+Inc
    Average 90 stars, based on 1 article reviews
    ag-specific tr1 cell medicinal product - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    T regulatory type 1 (Tr1)-mediated suppression in vivo . In steady-state condition, Tr1 cells reside in the spleen and circulate in the periphery. During inflammation, Tr1 cells are recruited to the site of tissue injury (i.e., after infections, autoimmune reactions, or transplantation) and are activated by professional antigen-presenting cells [APCs; dendritic cells (DCs)] via their T cell receptor, thus by their cognate antigen (Ag). Upon activation, Tr1 cells secrete IL-10 and TGF-β and (1) directly inhibit effector T cell (i.e., Th1 and Th17 cells) proliferation and pro-inflammatory cytokines production and (2) indirectly inhibit effector T cells by modulating professional APCs (i.e., downregulation of costimulatory and HLA class II expression and inhibition of pro-inflammatory cytokine secretion). (3) Tr1 cells can suppress effector T cells by cell-to-cell contact-mediated mechanisms, (4) suppress CD8 + T cell responses (i.e., proliferation and IFN-γ production), and (5) mediate bystander suppression by specifically killing professional APCs [DC or macrophages (M)], thus preventing naive T (Tn) cell priming and reactivation of effector T cells (i.e., Th1 and Th17 cells). Concomitantly, (6) Tr1 cells via IL-10 and TGF-β promote the induction of tolerogenic DC and anti-inflammatory macrophages (M2), which in turn promote de novo induction of Tr1 cells and T regulatory cells (Tregs), restoring tissue homeostasis and promoting long-term tolerance.

    Journal: Frontiers in Immunology

    Article Title: Engineered T Regulatory Type 1 Cells for Clinical Application

    doi: 10.3389/fimmu.2018.00233

    Figure Lengend Snippet: T regulatory type 1 (Tr1)-mediated suppression in vivo . In steady-state condition, Tr1 cells reside in the spleen and circulate in the periphery. During inflammation, Tr1 cells are recruited to the site of tissue injury (i.e., after infections, autoimmune reactions, or transplantation) and are activated by professional antigen-presenting cells [APCs; dendritic cells (DCs)] via their T cell receptor, thus by their cognate antigen (Ag). Upon activation, Tr1 cells secrete IL-10 and TGF-β and (1) directly inhibit effector T cell (i.e., Th1 and Th17 cells) proliferation and pro-inflammatory cytokines production and (2) indirectly inhibit effector T cells by modulating professional APCs (i.e., downregulation of costimulatory and HLA class II expression and inhibition of pro-inflammatory cytokine secretion). (3) Tr1 cells can suppress effector T cells by cell-to-cell contact-mediated mechanisms, (4) suppress CD8 + T cell responses (i.e., proliferation and IFN-γ production), and (5) mediate bystander suppression by specifically killing professional APCs [DC or macrophages (M)], thus preventing naive T (Tn) cell priming and reactivation of effector T cells (i.e., Th1 and Th17 cells). Concomitantly, (6) Tr1 cells via IL-10 and TGF-β promote the induction of tolerogenic DC and anti-inflammatory macrophages (M2), which in turn promote de novo induction of Tr1 cells and T regulatory cells (Tregs), restoring tissue homeostasis and promoting long-term tolerance.

    Article Snippet: An alternative method to induce/expand Ag-specific Tr1 cell medicinal product has been developed by the France-based company TxCell.

    Techniques: In Vivo, Transplantation Assay, Activation Assay, Expressing, Inhibition

    Protocols to generate/expand T regulatory type 1 (Tr1) cells. (A) Tr1-enriched cell lines. Donor-derived PBMC or CD4 + T cells are stimulated with host-derived monocytes in the presence of recombinant human IL-10 for 10 days. Alternatively, PBMC or CD4 + T cells are cultured for 10 days with allogenic dendritic cell (DC)-10, differentiated in vitro from peripheral blood monocytes with GM-CSF/IL-4/IL-10, in the presence of recombinant human IL-10 for 10 days . To generate T-allo10 cells, donor-derived T cells are cultured with host-derived DC-10 (Bacchetta and Roncarolo, unpublished data), whereas to induce host-derived T10 cells, T cells are stimulated with donor-derived DC-10 . (B) Tr1 cell clones. PBMC are stimulated with antigen (Ag; i.e., ovalbumin or collagen II) in the presence of IL-2 and IL-4 to enrich/expand Ag-specific T cells, followed by T cell cloning and expansion of the T cell clones using Schneider cells . (C) Tr1-like cell lines. Human CD4 + T cells are preactivated for 48 h with soluble anti-CD3/CD28 mAbs and IL-2 and then transduced with lentiviral vector (LV)-IL-10 overnight. Transduced T cells are isolated and expanded in feeder mixture . To generate allospecific IL-10-transduced cells, naive CD4 + T cells are stimulated with allogeneic DC and transduced with LV-IL-10 upon secondary stimulation. After selection, IL-10-trasduced cells are expanded in vitro with feeder mixture .

    Journal: Frontiers in Immunology

    Article Title: Engineered T Regulatory Type 1 Cells for Clinical Application

    doi: 10.3389/fimmu.2018.00233

    Figure Lengend Snippet: Protocols to generate/expand T regulatory type 1 (Tr1) cells. (A) Tr1-enriched cell lines. Donor-derived PBMC or CD4 + T cells are stimulated with host-derived monocytes in the presence of recombinant human IL-10 for 10 days. Alternatively, PBMC or CD4 + T cells are cultured for 10 days with allogenic dendritic cell (DC)-10, differentiated in vitro from peripheral blood monocytes with GM-CSF/IL-4/IL-10, in the presence of recombinant human IL-10 for 10 days . To generate T-allo10 cells, donor-derived T cells are cultured with host-derived DC-10 (Bacchetta and Roncarolo, unpublished data), whereas to induce host-derived T10 cells, T cells are stimulated with donor-derived DC-10 . (B) Tr1 cell clones. PBMC are stimulated with antigen (Ag; i.e., ovalbumin or collagen II) in the presence of IL-2 and IL-4 to enrich/expand Ag-specific T cells, followed by T cell cloning and expansion of the T cell clones using Schneider cells . (C) Tr1-like cell lines. Human CD4 + T cells are preactivated for 48 h with soluble anti-CD3/CD28 mAbs and IL-2 and then transduced with lentiviral vector (LV)-IL-10 overnight. Transduced T cells are isolated and expanded in feeder mixture . To generate allospecific IL-10-transduced cells, naive CD4 + T cells are stimulated with allogeneic DC and transduced with LV-IL-10 upon secondary stimulation. After selection, IL-10-trasduced cells are expanded in vitro with feeder mixture .

    Article Snippet: An alternative method to induce/expand Ag-specific Tr1 cell medicinal product has been developed by the France-based company TxCell.

    Techniques: Derivative Assay, Recombinant, Cell Culture, In Vitro, Clone Assay, Cloning, Transduction, Plasmid Preparation, Isolation, Selection

    Tr1 cells in clinical and preclinical development.

    Journal: Frontiers in Immunology

    Article Title: Engineered T Regulatory Type 1 Cells for Clinical Application

    doi: 10.3389/fimmu.2018.00233

    Figure Lengend Snippet: Tr1 cells in clinical and preclinical development.

    Article Snippet: An alternative method to induce/expand Ag-specific Tr1 cell medicinal product has been developed by the France-based company TxCell.

    Techniques: Clone Assay, In Vitro, In Vivo, Functional Assay